Conditions: Hepatic Encephalopathy
Keywords: Hepatic Encephalopathy Liver Failure Hepatic Insufficiency Liver Diseases Brain Diseases Rifaximin Cirrhosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

Detailed description:

Arms:
arm 1: Rifaximin, oral, 550 mg BID, 6 months of treatment arm 2: Placebo, oral, 0 mg BID, 6 months of treatment

Interventions: intervention 1: Placebo intervention 2: Rifaximin
Intervention descriptions: intervention 1: Placebo, oral, 0 mg BID, 6 months of treatment intervention 2: Rifaximin, oral, 550 mg BID, 6 months treatment

Protocol document: